1 Monster Stock to Hold for the Next 5 Years

Revenue rose 45% YoY to $4.9B in Q4 2025 and net income increased 50%, while Nu added 4M customers to reach 131M; average cost to serve is $0.80 vs ARPU of $15. The company holds a $33B loan book (mostly credit cards) with non-performing loans improving YoY, has obtained a U.S. bank charter with operations planned within 18 months, and sell-side consensus forecasts ~32% revenue CAGR from 2025–2028. Shares trade at a forward P/E of ~18.7 (below the S&P 500), presenting a valuation opportunity but warranting monitoring of credit quality and U.S. competitive risks.

Analysis

Nu’s U.S. charter is a strategic inflection, not just geographic expansion: the unit economics that worked in underbanked Latin America will face a higher CAC environment, denser regulatory capital and liquidity constraints, and direct competition against incumbents with deep deposit franchises. Expect a multi-quarter glide path where marketing spend, loss rates on new risk cohorts, and incremental RWAs reveal whether the firm can translate scale into incremental ROE or simply dilute returns while building share.

Second-order winners include fintech infrastructure vendors and card-processing partners that can export Nu’s stack into the U.S. and reuse product modules; conversely, mid-tier consumer banks in Brazil and Mexico face margin compression and may accelerate risk tightening, which could temporarily reduce credit growth in those markets. Also watch wholesale funding desks and dollar liquidity providers: if Nu shifts funding toward U.S. deposits, global deposit flows and short-term funding spreads for similar EM fintechs will reprioritize.

Tail risks crystallize through three mechanisms: a macro shock in Brazil/Colombia that elevates correlated card losses, a U.S. competitive price war that forces higher incentives to acquire customers, and regulator-driven capital increases after the charter that raise RWAs materially. Timeline: you can see early signals in the next 2–6 quarters; structural outcomes (capital raises, meaningful margin compression or re-rating) will likely play out over 12–24 months.

The consensus appears to underweight execution and funding friction rather than overestimate growth — market optimism is plausible if management demonstrates low incremental CAC and stable loss rates in new cohorts. For investors, the optimal stance is conditional: participate on controlled upside while explicitly hedging credit and execution vectors, and use quarterly credit metrics and charter disclosures as hard decision points to add or trim exposure.

Key Decisions for Investors

• Directional equity with credit hedge: Buy NU equity as a 12–18 month growth play on execution (entry on a pullback or post first U.S. pilot metrics), size 2–4% of active equity portfolio; finance protection by purchasing 12-month at-the-money puts sized to cover 50% of position (cost = premium). R/R: asymmetric upside if U.S. cohort economics hold; downside limited to put premium + equity drawdown if credit stress emerges.
• Cost-efficient upside via options spread: Buy NU 12–18 month call spread (buy nearer-term ATM call, sell higher strike OTM call) to limit premium outlay while capturing re-rate if RWAs remain benign and CAC proves low. R/R: capped upside but limited max loss = net premium; target 2:1 upside-to-cost if share re-rating occurs.
• Credit-first hedge: If unable to access CDS, buy 9–18 month NU put spreads to protect against rising non-performing loans or a capital raise (e.g., buy 30–60% OTM put, sell deeper OTM put). R/R: small upfront cost protects equity position against credit deterioration/restructuring over 12–18 months.
• Pair trade (eventual) — go long NU / short selected Latin American retail banks (e.g., ITUB, BBD) for 12 months to express share-shift thesis in consumer payment rails; initiate only after evidence of U.S. CAC efficiency or if incumbents report margin compression. R/R: benefits from Nu’s digital scale; risk that improving macro or regulatory tailwinds lift all domestic lenders together.